Isik, R. Et Al. 2001. p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. RESPIRATORY MEDICINE , vol.95, no.7 , 588-593.

Isik, R., Metintas, M., Gibbs, A., Metintas, S., Jasani, B., Oner, U., ... Harmanci, E.(2001). p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure. RESPIRATORY MEDICINE , vol.95, no.7, 588-593.

Isik, R Et Al. "p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure," RESPIRATORY MEDICINE , vol.95, no.7, 588-593, 2001

Isik, R Et Al. "p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure." RESPIRATORY MEDICINE , vol.95, no.7, pp.588-593, 2001

Isik, R. Et Al. (2001) . "p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure." RESPIRATORY MEDICINE , vol.95, no.7, pp.588-593.

@article{article, author={R Isik Et Al. }, title={p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure}, journal={RESPIRATORY MEDICINE}, year=2001, pages={588-593} }